Clinical trial
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a…
NCT00258700 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00258700 |
|---|---|
| Title | Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine |
| Official title | Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix™-IPV Versus a Licensed Men-C Vaccine With Pediacel™ When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Haemophilus Influenzae Type b, Neisseria Meningitidis |
| Intervention type | Biological |
| Interventions | Haemophilus influenzae type b- and meningococcal (vaccine) |
| Enrollment | 478 |
| Start date | Feb 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Nov 28, 2005 |
| Last update posted | Sep 21, 2016 |
| Countries | Poland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: